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Abstract 
Background: Mesenchymal stromal cells (MSC) with similar properties to bone marrow 
derived mesenchymal stromal cells (BM-MSC) have recently been grown from the limbus of 
the human cornea. We presently contribute to this novel area of research by evaluating 
methods for culturing human limbal MSC (L-MSC). Methods: Four basic strategies are 
compared: serum-supplemented medium (10% foetal bovine serum; FBS), standard serum-
free medium supplemented with B-27, epidermal growth factor, and fibroblast growth factor 
2, or one of two commercial serum-free media including Defined Keratinocyte Serum Free 
Medium (Invitrogen), and MesenCult-XF

 (Stem Cell Technologies). The phenotype of 
resulting cultures was examined using photography, flow cytometry (for CD34, CD45, 
CD73, CD90, CD105, CD141, CD271), immunocytochemistry (α-sma), differentiation 
assays (osteogenesis, adipogenesis, chrondrogenesis), and co-culture experiments with 
human limbal epithelial (HLE) cells. Results: While all techniques supported to varying 
degrees establishment of cultures, sustained growth and serial propagation was only achieved 
in 10% FBS medium or MesenCult-XF

 medium. Cultures established in 10% FBS medium 
were 70-80% CD34
-
/CD45
-
/CD90
+
/CD73
+
/CD105
+
, approximately 25% α-sma+, and 
displayed multi-potency. Cultures established in MesenCult-XF

 were >95% CD34
-
/CD45
-
/CD90
+
/CD73
+
/CD105
+
, 40% CD141
+, rarely expressed α-sma, and displayed multi-potency. 
L-MSC supported growth of HLE cells, with the largest epithelial islands being observed in 
the presence of MesenCult-XF

-grown L-MSC. All HLE cultures supported by L-MSC 
widely expressed the progenitor cell marker ∆Np63, along with the corneal differentiation 
marker cytokeratin 3. Conclusions: We conclude that MesenCult-XF
®
 is a superior culture 
system for L-MSC, but further studies are required to explore the significance of CD141 
expression in these cells.  
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Abbreviations 
APC - Allophycocyanin 
α-sma – Alpha smooth muscle actin 
BM-MSC – Bone marrow mesenchymal stromal cells 
CFE – Colony forming efficiency 
CK3 – Cytokeratin 3 
DK-SFM – Defined Keratinocyte Serum Free Medium 
DMEM – Dulbecco’s Modified Eagle’s Medium 
EGF – Epidermal growth factor 
FBS – Foetal bovine serum 
FGF-2 – Fibroblast growth factor 2 
FITC – Fluorescein isothiocyanate 
HLE – Human limbal epithelial 
HLS – Human limbal stromal 
L-MSC – Limbal mesenchymal stromal cells 
LSCD – Limbal stem cell deficiency 
MSC – Mesenchymal stromal cell 
NGS – Normal goat serum 
PBS – Phosphate buffered saline 
PE - Phycoerythrin 
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Introduction 
The limbus, or edge, of the cornea contains stem cells for regenerating the corneal epithelium 
(1). Diseases and injuries affecting the limbus can lead to a condition known as limbal stem 
cell deficiency (LSCD). The primary symptom of LSCD is loss of the corneal epithelium, 
which subsequently leads to chronic inflammation and scarring of the ocular surface. 
Advances in the treatment of LSCD have been achieved through use of cultured epithelial 
grafts prepared from limbal tissue. Traditionally, these epithelial grafts are grown from limbal 
tissue explants cultured on donor amniotic membrane (2-4). Alternatively, dissociated limbal 
tissue has been subjected to ex vivo expansion in the presence of growth-arrested murine 
fibroblast feeder cells (5-7). Logically, the therapeutic benefits of cultured limbal grafts are 
primarily due to the presence of a robust population of poorly differentiated epithelial cells, 
but these are not the only cell type present.  
Cultures of limbal epithelium contain variable numbers of contaminating human 
limbal stromal (HLS) cells (8). Based upon simple morphological criteria, these 
contaminating stromal cells have been referred to as “fibroblasts” or “keratocytes”, but a 
recent comparison with bone marrow derived mesenchymal stem/stromal cells (BM-MSC) 
has revealed a similar profile of cell surface markers and evidence of multi-potency (8). The 
discovery of limbal mesenchymal stromal cells (L-MSC) raises significant questions 
regarding the potential role of stromal cells in cultured limbal grafts and may well lead to 
improved strategies for corneal tissue engineering. To this end, we have presently evaluated a 
range of different culture methods with the view to optimising L-MSC yield and purity for 
subsequent clinical use. 
Current techniques for growing L-MSC are based upon use of serum-supplemented 
growth medium (8-10). While providing an effective source of cell attachment and growth 
factors, the properties of serum can vary significantly from batch to batch or between donors 
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thus leading to inconsistent results. Moreover, serum contains factors that promote cell 
differentiation, which could potentially lead to a reduction in product efficacy. Thus an ideal 
method for growing L-MSC would be one that supports high yields with minimal 
differentiation. A review of methods for growing cells (MSC or keratocytes) from either the 
limbal or corneal stroma revealed a variety of strategies for exploration (Table 1). To begin, 
cultures that are simply maintained in serum-supplemented medium display characteristics 
similar to those of BM-MSC; however, they also contain differentiated cells including 
myofibroblasts (8-10). Secondly, cultures can be initiated in the presence of serum then 
switched to serum-free medium containing a number of defined growth factors (11). 
Alternatively, completely serum-free techniques can be used (12-14). Use of serum-free 
media with corneal stromal cells appears to have maintained these cells in a poorly 
differentiated state, but the degree of proliferation observed in these cultures is not clear.  
 Based upon consideration of the above, we have evaluated four basic strategies for 
growing L-MSC: serum supplemented medium, conventional serum-free medium 
supplemented with defined growth factors previously used to support stromal cells, and two 
commercial serum-free media, Defined Keratinocyte Serum-Free Medium (DK-SFM; 
Invitrogen) and MesenCult-XF
® 
(Stem Cell Technologies). Our results demonstrate marked 
differences in L-MSC phenotype under each growth condition and provide evidence of a 
novel marker for L-MSC.  
 
Materials and methods 
 
Establishment of cultures from limbal stroma 
Human corneoscleral rims were obtained with ethics approval and donor consent from the 
Queensland Eye Bank (QEB), Brisbane, Australia. Prior to digestion, the tissue was dissected 
6 
 
down to a 1.5 - 2 mm diameter across the limbal transition between transparent cornea and 
white sclera. The tissue was then washed in three changes of phosphate buffered saline (PBS) 
to remove storage medium, then digested with 0.25% dispase (Invitrogen, VIC, Australia) for 
1 h at 37 ºC to assist removal of HLE cells. In later experiments the HLE was retained for co-
culture experiments with stromal cells (see below). The remaining stroma was digested in 1 
mg/ml Collagenase Type I (Invitrogen, VIC, Australia) for 48 h in DMEM/F12 (Invitrogen, 
VIC, Australia). The dissociated stromal cells were washed and initially seeded at a density 
of 5 × 10
3
 cells/mL where possible under four different culture conditions. The first culture 
condition consisted of DMEM/F12 medium supplemented with 10% foetal bovine serum 
(FBS; Hyclone Thermo Scientific, VIC, Australia), thus mimicking the approach most 
commonly used in previous studies including our own (8-10). For simplicity this first 
medium is subsequently referred to as 10% FBS medium. The second approach (hereafter 
referred to as 2% B-27 medium) was based upon the method of Mimura et al. (14), in which 
cultures are grown in DMEM/F12 medium supplemented with 2% B-27, 1% insulin 
transferrin selenium (ITS) supplement, 20 ng/mL epidermal growth factor (EGF) and 40 
ng/mL fibroblast growth factor 2 (FGF-2) (all Invitrogen, VIC, Australia). The third 
technique was based upon the method of Kawakita et al. (13) using Defined Keratinocyte 
Serum-Free Medium (DK-SFM; Invitrogen, VIC, Australia), and was compared to 
MesenCult®-XF culture system (Stem Cell Technologies, VIC, Australia), a serum-free 
culture system designed for cultivation of human-derived MSC. All media were additionally 
supplemented with 1% penicillin/streptomycin solution (Invitrogen, VIC, Australia). Finally, 
subsequent studies investigated the effects of establishing cultures in 10% FBS medium, then 
subculturing in each of the original serum-free media as well as DMEM/12 medium 
supplemented with 10 ng/mL FGF-2 alone.  
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Establishment of primary BM-MSC cultures 
Human BM-MSC were used as a positive control for studies involving assessment of MSC 
phenotype and differentiation potential with human L-MSC. All BM-MSC experiments were 
approved by the Mater Health Services Human Research Ethics Committee. Briefly, up to 
20ml of bone marrow aspirate was removed from the iliac crest from a healthy donor.  The 
sample was then underlayed with Ficoll and centrifuged at 535 g for 20 min at 20C, with no 
brake. The interface layer was then removed and transferred to a separate tube. This was then 
washed with PBS and centrifuged at 350 g for 5 min with brake. The supernatant was then 
discarded and the cell pellet resuspended and plated in culture with DMEM (low glucose; 
Invitrogen, VIC, Australia) supplemented with 20% FBS and 1% 
penicillin/streptomycin/glutamine solution (Invitrogen, VIC, Australia).  
 
Flow cytometry 
Cellular phenotype analysis was performed on L-MSC and BM-MSC by flow cytometry 
using fluorescently labelled mouse anti-human antibodies as follows: IgG1 к isotype control 
phycoerythrin (PE) (MOPC-21), CD34 fluorescein isothiocyanate (FITC) (581/CD34, IgG1 
к), CD45 PE-cyanine dye (Cy7) (HI30, IgG1 к), CD73 allophycocyanin (APC) (AD2, IgG1 
к), CD90 APC (5E10, IgG1 к), CD105 PE (SN6, IgG1 к), and CD141 PE (1A4, IgG1 к). All 
antibodies were purchased from Becton-Dickinson (BD Pharmingen, CA, USA) or 
Ebioscience (in the case of CD73 and CD105; Jomar Bioscience, SA, Australia). Viability 
was assessed by 7-amino-actinomycin D incorporation (BD Viaprobe cell viability solution). 
Antibody concentrations were used according to manufacturers’ instructions. Fifty thousand 
events were collected on a BD LSRII (BD Biosciences, CA, USA) and analysed using 
FlowJo software (Tree Star Inc., OR, USA). Cell subsets were defined as follows: MSC  
(CD45
-
/CD90
+
/CD73
+
/CD105
+
) (15,16), putative keratocyte marker (CD34
+
) (17,18), 
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fibroblasts (CD90
+
), myofibroblasts (CD90
+
/-sma+), putative epithelial cell marker 
(CD141
+
) (19,20), vascular endothelial cells (CD34
+
/CD141
+
), bone marrow derived cells 
(CD45
+
) and glial cells (CD271
+
). 
 
MSC differentiation studies 
Evidence of multi-potency was investigated by growing cultures of HLS cells (initially 
cultivated in 10% FBS and MesenCult-XF
®
) under osteogenic, chondrogenic, and adipogenic 
inductive conditions. Cultures of human BM-MSC were used as a positive control. For 
osteogenic conditions, cells were seeded at 10
4
 cells/cm
2 
and grown for 3 weeks in osteogenic 
medium (DMEM medium supplemented with 0.1 μM dexamethasone, 10 mM β-glycerol 
phosphate, 200 μM L-ascorbate-2-phosphate, 4 mM calcium chloride CaCl2, 10% FBS and 
1% penicillin/streptomycin/glutamine (PSG) solution) before fixation in 4% buffered 
formalin and staining with Alizarin red. For adipocyte differentiation, cells were initially 
seeded at 5 × 10
4
 per well (24 well plate) in 10% FBS media and cultured overnight before 
being grown for 3 weeks in adipocyte differentiation medium (DMEM medium 
supplemented with 0.5 mM IMBX, 60 μM indomethacin, 5 μg/mL insulin, 1 μM 
dexamethasone, 10% FBS, and 1% PSG), fixed in formalin, and stained for lipid formation 
using Oil-red O. For chondrocyte differentiation, 5 × 10
5
 cells were collected and placed in a 
15 mL tube, centrifuged at 300 g for 5 min to form a cell pellet, and the overlaying 
supernatant gently replaced with 500 μl of chondrocyte differentiation media (DMEM 
medium supplemented with 0.1 μM dexamethasone, 0.2 mM ascorbic acid 2 phosphate, 1 
mM sodium pyruvate, 40 ug/mL proline, 10 ng/mL TGF-β3, 5 μg/mL ITS, and 1% PSG 
solution). After 3 weeks culture, pellets were fixed in formalin and processed for either 
paraffin or frozen sectioning before staining with Alcian Blue and performing 
immunohistochemistry for Collagen II. 
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Immunostaining 
Immunocytochemistry was performed to determine the expression of α-sma in passage 2 
HLS cell cultures grown in 10% FBS and MesenCult-XF
®
, and later to examine the 
phenotype of HLE cells in co-culture experiments (cytokeratin 3 and ΔNp63). Briefly, 
cultures were fixed in 10% buffered formalin, briefly washed in PBS, then blocked and 
permeabilised in 0.1% Triton X-100 with 5% normal goat serum (NGS) in PBS for 1 h at 37 
ºC. Cultures were then incubated separately with each primary antibody for 1 hr in 1% 
NGS/PBS. An Alexa Fluor 488 goat anti-mouse IgG secondary antibody (Invitrogen, VIC, 
Australia) was used to detect antibodies to α-sma (Dako Australia Pty Ltd, VIC, Australia) 
and cytokeratin 3 (CK3; Millipore, VIC, Australia), and an Alexa Fluor 594 goat anti-rabbit 
secondary antibody (Invitrogen, VIC, Australia) was applied to detect antibody to ΔNp63 
(Biolegend, Australian Biosearch, WA, Australia). All secondary antibodies were applied for 
1 h at 37 ºC and all cultures were counterstained with Hoechst nuclear dye for 15 minutes.  
Immunohistochemistry was performed on L-MSC and BM-MSC chondrogenic 
differentiation pellets for Collagen Type II (II-II6B3; Developmental Studies Hybridoma 
Bank, Iowa, USA) with a VECTASTAIN Elite ABC-Peroxidase kit (Vector Laboratories, 
Abacus ALS, QLD, Australia) according to manufacturers’ instructions. 
 
Co-culture experiments with HLE 
Sheets of HLE obtained from dispase-treated tissue were dissociated by treatment with 0.25% 
trypsin in 0.2 g/L EDTA (Invitrogen, VIC, Australia) for 5 min then washed and resuspended 
in epithelial growth medium (EGF) consisting of a  mixture of 3 parts DMEM with 1 part 
F12 medium (both from Invitrogen, VIC, Australia), supplemented with 10% FBS, 1% 
penicillin/streptomycin solution, 10 ng/mL EGF, 1% v/v non-essential amino acids, 400 µM 
L-glutamine (all Invitrogen, VIC, Australia), 6.8 mg 3,3,5-triiodo-L-thyronine sodium salt, 
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180 µM adenine, 5 µg/mL transferrin, 0.4 µg/mL hydrocortisone, 1 µg/mL insulin (all 
Sigma-Aldrich, NSW, Australia), and 10
-5
 M isoproterenol (Calbiochem, Merck, VIC, 
Australia).  
 The ability of HLS cells to serve as feeder cells for HLE growth was examined in 
comparison with the gold-standard (murine 3T3 fibroblasts). The murine 3T3 fibroblast 
feeder cells (ATCC; CCL-92) were maintained in DMEM supplemented with 10% FBS and 
400 µM L-glutamine prior to use. HLE cell cultures were established by seeding freshly 
isolated cells into 75 cm
2
 flasks at a density of 5 × 10
5
 cells in the presence of 2 × 10
6
 feeder 
cells (either 3T3 fibroblasts or HLS cells grown in either 10% FBS medium or MesenCult-
XF
®
). All feeder cells were growth-arrested prior to seeding by gamma irradiation (4 x 25 
gray). HLE cultures were grown to approximately 80-90% confluency, before being 
subcultured for 5 days in the absence of feeder cells and examined by immunocytochemistry 
for CK3 and Np63 (as described above). 
 The effects of each feeder cell type on the colony-forming efficiency (CFE) of HLE, 
was also examined using standard techniques. In brief, standard cultures of HLE were 
established as above with 3T3 feeders, then seeded at a density of 170 cells per cm
2
 into a 6 
cm petri dish in the presence of 8.3 × 10
4
 cells/cm
2 
of either 3T3 or HLS feeder cells. After 
14 days the cultures were fixed in formalin and stained with Rhodamine B Solution (Sigma 
Aldrich, NSW, Australia) to demonstrate epithelial colonies. The number of colonies (defined 
as 20 cells or more) was expressed as a percentage of the original seeding density: (number of 
colonies counted/number of cells plated) × 100.  
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Results 
 
Establishment of cultures from limbal stroma 
Freshly isolated HLS cells cultured in 10% FBS medium adopted a regular spindle-shaped 
morphology and reached 80-90% confluence within 14 days on average (Fig. 1A). 
MesenCult-XF
®
 supported similar growth to confluency, but the cells displayed a thinner and 
more elongated spindle shape than those grown in the presence of serum (Fig. 1D). DK-SFM 
supported attachment and growth of spindle-shaped cells, but confluency was rarely observed 
except in a few cultures after approximately 30-50 days (Fig. 1B). Cells grown in serum-free 
medium supplemented with defined growth factors (abbreviated as 2% B-27 medium), 
formed non-adherent spherical aggregates, but resulted in poor yields (Fig. 1C). Average 
yields from at least 3 individual donors at passage (p) 0 in a 24 well plate were 7.6 × 10
4
 for 
10% FBS medium, 7.0 × 10
3
 for DK-SFM, 6.0 × 10
3
 for 2% B-27, and 3.4 × 10
5 
for 
MesenCult-XF
®
. 
 
Propagation of cultures from limbal stroma 
A direct comparison of serial growth when cells were maintained in each of the primary 
media used for three passages (Fig. 2), revealed highest yields in MesenCult-XF
®
 medium 
(2.94 × 10
6
 per T75 flask) followed closely by serum-supplemented medium (1.92 × 10
6
 per 
T75 flask). In contrast, p0 cultures achieving confluency in DK-SFM, subsequently failed to 
thrive when passaged in this commercial serum-free medium. 
Cultures established in the presence of 10% FBS, failed to thrive following transfer to 
DK-SFM, 2% B-27 medium, or 10 ng/mL FGF-2 (Fig. 3B, 3C, and 3D), but grew well in 
MesenCult-XF
®
 medium (Fig. 3E). Average cell yields from at least 3 individual donors at 
p1 in a T25 flask were 1.1 × 10
6
 for 10% FBS, 1.6 × 10
5
 cells for DK-SFM, 9.7 × 10
3
 cells 
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for 2% B-27 medium, 7.7 × 10
3
 cells for 10 ng/mL FGF-2 medium, and 2.6 × 10
6
 cells for 
MesenCult-XF
®
. Cultures that failed to thrive in serum-free medium at p0 also did not 
improve when transferred to low-serum (1% FBS) containing medium at p1 (data not shown).  
 
Phenotype of cultures from limbal stroma 
HLS cells established in 10% FBS medium displayed positive expression of CD90, trace 
expression of CD141 and CD271, and 81.04% (± 1.65 SEM) of live cells expressed the 
characteristic MSC markers of CD34
-
, CD45
-
, CD90
+
, CD73
+
, CD105
+
 (Fig. 1E). Serum 
cultivated BM-MSC, as a positive control, were 99% CD34
-
, CD45
-
, CD90
+
, CD73
+
, CD105
+
 
but negative for CD141 at passage 2 (data not shown). Approximately 25% of HLS cells 
grown in the presence of serum stained positively for -sma at passage 2 (Fig. 4A, 4B, and 
4C), similarly to BM-MSC (Fig. 4G, 4H, and 4I). HLS cells cultured in DK-SFM also had 
positive expression of CD90; however, this cell population was 58.43% (± 10.45 SEM) 
positive for the characteristic MSC markers. DK-SFM cultures contained a quarter of live 
cells which were positive for CD141 (29.44 ± 8.45%; Fig. 1F). The cultures established in 
2% B-27 medium had less CD90 cell surface expression than the previous culture methods; 
however, they had an increase in CD34 quiescent keratocyte expression, and trace amounts of 
CD141, CD271, and MSC markers (Fig. 1G). MesenCult-XF
®
 cultures contained 96.04% (± 
0.61 SEM) cells which expressed a characteristic MSC phenotype and had positive 
expression (38.37 ± 0.28%) of CD141 (Fig. 1H). Staining for -sma was rarely observed in 
MesenCult-XF
®
 HLS cell cultures at passage 2 (Fig. 4D, 4E, and 4F). Overall, HLS cells 
cultured in 10% FBS medium and the MesenCult-XF
®
 culture system produced the most 
consistent phenotype as judged by the relative size of error bars. 
For cultures established in serum, marked changes in phenotype were observed when 
switched to serum-free media. Cultures changed into DK-SFM displayed an increase in 
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CD34 and CD90 cell surface expression, and a decrease in CD141 and MSC profile 
expression (Fig. 3G). HLS cell cultures switched to 2% B-27 medium became more uniform 
with a predominant CD90 phenotype (Fig. 3H). Serum-free cultures supplemented with only 
FGF-2 contained ~35% cells positive for CD90 (36.91 ± 8.35%) and the MSC markers 
(32.88 ± 10.45%; Fig. 3I). The 2% B-27 and FGF-2 cultures also had a proportion of cells not 
positive for any of our specified markers. Cultures switched to MesenCult-XF
®
 contained 
more cells with the MSC characteristic phenotype and more CD141 expression (Fig. 3J) than 
cells maintained in serum-supplemented medium. Cells maintained throughout in serum-
supplemented medium displayed fewer MSC (71.90 ± 2.10%) at p1 than observed in p0 
cultures (>80%), but retained high numbers of CD90 expression (98.24 ± 0.33%; Fig. 3F).  
 
Differentiation potential of cultures from limbal stroma 
HLS cells grown in 10% FBS medium and the MesenCult-XF
®
 culture system, along with 
BM-MSC grown in serum-supplemented medium, displayed expression of osteogenic (Fig. 
5B, 5G, and 5L), adipogenic (Fig. 5C, 5H, and 5M), and chondrogenic (Alcian Blue, Fig. 5D, 
5I, and 5N; Collagen II, Fig. 5E, 5J, and 5O) potential.  Osteogenic and chondrogenic 
potential was similar among all cohorts; however, 10% FBS medium supported lower 
adipogenic expression compared with MesenCult-XF
®
 and BM-MSC cultures. 
 
Response of limbal epithelial cells to limbal stromal cells when used as feeders 
After thoroughly analysing the phenotype of the limbal stromal cells, we sought to investigate 
one application of their use, as a feeder layer for HLE cells. Limbal stromal cell cultures 
grown in 10% FBS medium or MesenCult-XF
®
 medium were able to support the growth of 
HLE cells comparably to 3T3 feeder cells (Fig. 6D). Based simply upon the number of 
discrete islands, the 3T3 feeder cells displayed the best CFE with an average of 5.5% 
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(compared to 0.86% for 10% FBS and 0.48% for MesenCult-XF
®
 feeders); however, a 
realistic comparison with MesenCult
®
 cultures was not feasible owing to apparent rapid 
expansion and connectivity of islands. As such the mean diameter of HLE colonies varied 
greatly between 3T3 feeders (~3mm), 10% FBS feeders (~9mm), and MesenCult-XF
®
 
feeders (~1.5cm). Limbal epithelial morphology on all feeder layers remained similar (Fig. 
6A, 6B, and 6C). 
CK3 was expressed in all HLE cultures, with faint expression on lower layers and 
brighter expression on stratified portions of the cell layers (Fig. 7). 3T3 feeders contained the 
most stratified epithelium (Fig. 7A, 7B, and 7C), with the limbal feeders having smaller 
proportions of CK3 bright cells (Fig. 7E, 7F, 7H, and 7I). ΔNp63 nuclear expression was 
seen in HLE cells cultured on all feeder layers (Fig. 8). However, the 10% FBS cohort 
displayed larger and more sparse HLE nuclei (Fig. 8E) compared with 3T3 (Fig. 8B) and 
MesenCult-XF
®
 (Fig. 8H) feeder layers which produced smaller and more densely packed 
HLE nuclei. 
 
Discussion 
The limbal epithelium has been widely recognized as a source of epithelial progenitor cells 
for corneal tissue engineering (4,6,7,21,22). Hence, the recent discovery of stromal 
progenitor cells with characteristics similar to that of BM-MSC is likely to lead to further 
innovative therapies (8,10). Potential applications of L-MSC include use as feeder cells for ex 
vivo expansion of epithelial progenitor cells, thus replacing the requirement for murine 3T3 
feeder cells. Alternatively, L-MSC could be used in their own right as a cellular therapy for 
reconstruction of the limbal or corneal stroma. An important step in developing these 
applications is to establish appropriate techniques for L-MSC isolation and culture. Thus we 
have evaluated in this study a range of current methods for growing HLS cells along with a 
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recently developed commercial product for growing human-derived MSC. Our results 
demonstrate that while serum-supplemented growth medium provides an effective method for 
generating and propagating L-MSC, these cells can be grown in larger quantities and to a 
higher degree of purity using the MesenCult-XF

 culture system. Nevertheless, the 
unexpected finding of elevated CD141 expression in cultures grown using the MesenCult-
XF

 system raises some significant questions for further exploration.  
 To understand the significance of our results, the anatomy of the limbus should be 
considered. Unlike the central corneal stroma which contains relatively few cell types 
(including resident CD34
+
 keratocytes), the limbus contains peripheral keratocytes, 
fibroblasts, melanocytes, immune cells including dendritic cells, and various cell types 
associated with blood vessels (vascular endothelial cells, pericytes and smooth muscle cells) 
and nerve fibers (Schwann cells and fibroblasts). Moreover, the potential for contaminating 
limbal epithelial cells or differentiated stromal cells must also be considered.  
 The phenotype of HLS cell cultures grown in the presence of 10% FBS is similar to 
that for BM-MSC including the expression of -sma and suggests that few, if any, other cell 
types are present with the exception of differentiated fibroblasts and myofibroblasts. Based 
upon the previous results of others (Table 1), we had predicted that use of serum-free growth 
medium supplemented with a defined combination of growth factors, would increase the 
number and purity of progenitor-like cells with either an MSC or keratocyte profile, but 
unfortunately this proved not to be the case. These serum-free techniques proved to be 
unsuitable for routine cultivation of any HLS cell type due to the poor growth observed. The 
MesenCult-XF
®
 culture system was developed with the intent of providing a more defined 
and higher performing alternative to the use of serum-supplemented medium for routine 
cultivation of human-derived MSC. Interestingly, Pal et al. (23) concluded that MesenCult-
XF
®
 performs less well that serum-supplemented growth medium for BM-MSC due to 
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apparent senescence after approximately 6 passages. Based upon our prior clinical experience 
of cultured HLE cells, we did not consider the need to grow stromal cells beyond passage 3 in 
the current study, and thus it remains possible that extended cultivation might reveal similar 
results. In the absence of such further data, however, we conclude that, based upon the 
superior growth and increased purity of L-MSC (including lower numbers of myofibroblasts) 
using the MesenCult-XF
®
 culture system, this should be considered as a alternative to use of 
serum-supplemented medium. Nevertheless, the unexpected increase in CD141 expression 
warrants further investigation.  
 The cell surface marker CD141, or thrombomodulin is a co-factor of thrombin-
catalyzed activation of protein C, which in turn inhibits the pro-coagulant functions of 
thrombin. Thrombomodulin is located on cells such as endothelium, keratinocytes, 
osteoblasts, and macrophages, in which it may be involved in cell differentiation or in 
inflammation (24). Based upon this knowledge it is possible that a number of cells grown in 
MesenCult-XF
®
 may have commenced partial differentiation into vascular endothelial cells. 
If true, this could be problematic for use of this growth medium in therapies for treating the 
cornea since the corneal stroma is normally avascular and indeed a vascularised corneal 
stroma (corneal neovascularisation) is a common feature of chronic corneal disease. 
Alternatively, the use of this medium may well be appropriate for reconstructing rings of 
limbal tissue since vascularisation of this tissue is considered a contributor to maintaining the 
epithelial stem cell niche.  
We have previously reported that HLS cells cultured in serum-supplemented media 
can adequately support the growth of HLE cells (9). In this study, L-MSC supported an HLE 
layer which retains vital similarities in HLE cell phenotype and morphology compared to 
those produced on 3T3 feeder cells. Importantly, it is unlikely that the epithelial islands could 
have arisen in part from mesenchymal-to-epithelial transformation since all feeder cell used 
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in the study were growth arrested by gamma irradiation prior to use. Furthermore, the clinical 
efficacy of cultivated HLE grafts relies upon the phenotype of the grafted cells.  Importantly, 
there was evidence of CK3 expression and abundant expression of the progenitor marker 
ΔNp63, which is highly desirable for clinical efficacy (9,22). These results also concur with 
those reported in the use of BM-MSC as a feeder layer for HLE (25).  
In conclusion, our studies demonstrate the ability to consistently culture L-MSC 
serum-free using the MesenCult-XF
®
 culture system while maintaining the defined MSC 
characteristic phenotype; however, further investigation of CD141 expression is warranted. 
L-MSC also supported the cultivation of limbal epithelium of a clinically appropriate 
phenotype. Optimisation of this method could be achieved by determining a serum-free 
method which supports the co-culture of L-MSC and HLE cells. The potential benefits of L-
MSC in tissue engineered corneal models should also be explored. 
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 Table 4.1. Summary of methods used previously to grow stromal cells from the cornea and corneal limbus. Abbreviations are as follows: 
BrDU – bromodeoxyuridine; DMEM – Dulbecco’s Modified Eagle Medium; FBS – foetal bovine serum; EGF – epidermal growth factor; PDGF 
– platelet-derived growth factor; ITS – insulin, transferrin, selenium; LIF – leukaemia inhibitory factor; BSA – bovine serum albumin; FGF-2 – 
fibroblast growth factor 2; HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. 
Reference Cell 
Source 
Isolation method Culture method Propagation Phenotype/ 
Multi-potency 
Choong et al. 
(2007)
 
 
Human 
corneal 
stroma 
Corneal explant technique. 
Corneal stromal was chopped 
into fine pieces. 
DMEM supplemented with 10% FBS, 0.05 
U/mL penicillin and 0.05 U/mL 
streptomycin. 
Passaged 4 
times. 
CD13
+
, CD29
+
, CD44
+
, 
CD56
+
, CD73
+
, CD90
+
, 
CD105
+
, CD133
+
. HLA-DR
-
, 
CD34
-
, CD117
-
 & CD45
-
. 
Multi-potent. 
Polisetty et al. 
(2008)  
Human 
limbal 
biopsy 
Established from explant 
then enriched by passaging.  
Human corneal epithelial medium with 10% 
FBS. 
Passaged 6 
times. 
CD105
+
, CD106
+
, CD54
+
, 
CD166
+
, CD90
+
, CD29
+
, 
CD71
+
, pax6
+
. p75
-
, SSEA1
-
, 
Tra-1-61
-
, Tra-1-81
-
, CD31
-
, 
CD34
-
, CD45
-
, CD11a
-
, 
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CD11c
-
, CD14
-
, CD138
-
, Flk1
-
, Flt1
-
, VE-Cadherin
-
. Multi-
potent. 
Ainscough et al. 
(2011) 
Human 
limbal 
stroma 
2 mm stromal biopsies from 
the limbus were digested for 
48 h in 0.05% collagenase 
prepared in growth medium. 
DMEM supplemented with 10% FBS. Passaged 16 
times. 
Vimentin
+
, CD90
+
. CD34
-
, 
CD45
-
, CD141
-
, CD271
-
. 
Du et al. (2005) Human 
corneal 
stroma 
Minced into 2 mm cubes. 
Stroma was digested up to 3 
h at 37ºC in DMEM with 1 
mg/mL collagenase + 0.2 
mg/mL testicular 
hyaluronidase. 
DMEM/MCDB-201 supplemented with 2% 
FBS, 10 ng/mL EGF, 10 ng/mL PDGF, 5 
ug/mL ITS, 1,000 U/mL LIF, x1 linoleic 
acid-BSA, 0.1 mM ascorbic acid-2-
phosphate, 10-8 M dexamethansone, with 
antibiotics. ABCG2
+
 subpopulation 
subcultivated in Advanced DMEM 
supplemented with 10 ng/mL FGF-2. 
Unknown. keratocan
+
; keratan sulfate
+
; 
ALDH
+
. Multi-potent. 
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Kawakita et al. 
(2006) 
Primate 
corneal 
stroma 
Digested at 37°C for 16 h in 
2.5 mL of DMEM containing 
1 mg/mL collagenase A, 20 
mM HEPES, 50 g/mL 
gentamicin, and 1.25 g/mL 
amphotericin B. 
Defined Keratinocyte Serum-Free Medium. Passaged 14 
times. 
CD34
+
, keratocan
+
, ALDH
+
 
Mimura et al. 
(2008) 
Rabbit 
corneal 
stroma 
Overnight digestion in 0.02% 
collagenase. 
DMEM/F12 supplemented with B-27, 20 
ng/ml EGF, 40 ng/mL FGF and 0.8% 
methylcellulose gel matrix. 
Unknown. BrDU
+
, keratocan
+
,  vimentin
+
. 
Funderburgh et 
al. (2008) 
Bovine 
corneal 
stroma 
Digestion for 1 hour in 1 
mg/mL collagenase. Placed 
overnight on ice, before 2-4 h 
incubation with 10 mg/mL 
collagenase 
Primary keratocytes were suspended in 
protein free DMEM plus antibiotics, or in 
advanced DMEM (with ITS) plus antibiotics. 
Cells were placed in tissue culture dishes 
coated with polyHEMA at 37°C. 
Unknown. BrDU
+
, keratocan
+
, keratan 
sulfate
+
, lumican
+
. 
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Figure 1. Morphology and phenotype of cultures established from limbal stroma at passage 
0. Representative phase contrast images of cultures established in either DMEM/F12 with 
10% foetal bovine serum (10% FBS medium; part A), Defined Keratinocyte Serum-Free 
Medium (DK-SFM; part B), DMEM/F12 medium containing B-27 supplement, insulin, 
transferrin, selenium (ITS), epidermal growth factor (EGF) and fibroblast growth factor 2 
(FGF-2) (2% B-27 medium; parts C & G), or using the MesenCult-XF
®
 serum-free culture 
system designed for human derived mesenchymal stromal cells (MSC; part D). (Parts E, F, G 
& H) Corresponding percentage of live cells in cultures that are positive for CD34, CD45, 
CD90, CD141, CD271, or the MSC characteristic markers (CD45
-
CD73
+
CD90
+
CD105
+
) by 
flow cytometry. Bars are mean ± SEM. All flow cytometry was performed on a minimum of 
three individual donors with three replicates per donor. Scale bar = 200 µm. 
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Figure 2. Response of limbal stromal cell cultures to serial propagation. Cultures were 
propagated in either DMEM/F12 with 10% foetal bovine serum (10% FBS medium) (■), 
Defined Keratinocyte Serum-Free Medium (DK-SFM; Δ), DMEM/F12 medium 
supplemented with 2% B-27, insulin, transferrin, selenium (ITS), epidermal growth factor 
(EGF) and fibroblast growth factor 2 (FGF-2) (2% B-27 medium; □), or MesenCult-XF® 
medium (▲). Values at each passage point indicate either the total number of cells initially 
seeded into culture (p0), or total number of cells subsequently harvested after sequential 
growth in one well of a 24-well culture plate (p1), a 25 cm
2
 culture flask, or a 75 cm
2
 culture 
flask. All cultures were harvested together when confluency was achieved in serum-
supplemented medium. Bars represent mean ± SEM for up to 8 different tissue donors.  
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Figure 3. Morphology and phenotype of cultures established from limbal stroma in serum-
supplemented medium before propagation in serum-free medium. Cultures were established 
in serum-supplemented growth medium, before being passaged into either DMEM/F12 with 
10% foetal bovine serum (10% FBS medium, part A), Defined Keratinocyte Serum-Free 
Medium (DK-SFM; part B), DMEM/F12 medium supplemented with 2% B-27, insulin, 
transferrin, selenium (ITS), epidermal growth factor (EGF) and fibroblast growth factor 2 
(FGF-2) (2% B-27 medium; parts C & H), DMEM/F12 supplemented with 10 ng/mL FGF-2 
(part D), or using the MesenCult-XF
®
 serum-free culture system (part E). (Parts F, G, H, I & 
J) Corresponding percentage of live cells in cultures that are positive for CD34, CD45, CD90, 
CD141, CD271, or the characteristic mesenchymal stromal cell markers (CD45
-
CD73
+
CD90
+
CD105
+
) by flow cytometry. Bars are mean ± SEM. All flow cytometry was 
performed on a minimum of three individual donors with three replicates per donor. Scale bar 
= 200 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
 
Figure 4. Expression of α-sma in limbal stromal cultures. Demonstration of Hoechst nuclear 
staining (parts A, D & G) and alpha smooth muscle actin (α-sma; parts B, E & H) expression 
by immunocytochemistry in passage 2 cultures of limbal mesenchymal stromal cells (MSC) 
grown in either serum-supplemented growth medium (parts A & B) or using the MesenCult-
XF
®
 culture system (parts D & E), compared with passage 2 bone marrow derived MSC 
(parts G & H). Inserts in parts B, E & H display negative controls for respective cell types. 
Parts C, F & I show a magnified image of that in parts B, E & H. Scale bars = 200 µm. Scale 
bar in part C corresponds to magnified images in parts C, F & I. 
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Figure 5. Demonstration of multi-potency by stromal cell cultures derived from limbal tissue. 
Limbal mesenchymal stromal cell (MSC) cultures established in either serum-supplemented 
growth medium (parts A to E), or using the MesenCult-XF
®
 culture system (parts F to J) 
were grown for 3 weeks under either osteogenic (parts B, G & L), adipogenic (parts C, H & 
M) or chondrogenic conditions (Alcian Blue, parts D, I & N; Collagen II, parts E, J & O) 
before staining with Alizarin Red (areas of calcification), Oil-Red-O (lipid droplets), Alcian 
Blue (acid mucosubstances), or Collagen Type II (marker of cartilage extracellular matrix) 
respectively. Corresponding results using BM-MSC are shown in parts K to O. Scale bar = 
200 μm. 
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Figure 6. Human limbal epithelial (HLE) colony formations supported by limbal stromal 
feeders. Results of attempt to perform colony forming efficiency (CFE) assays with HLE 
cells co-cultured with either stromal cell cultures established in presence of serum (part A), 
murine 3T3 fibroblasts (part B), or stromal cell cultures established using the MesenCult-XF
®
 
culture system (part C). Corresponding images of each culture dish including example of 
HLE seeded alone is displayed in part D. The confluency of HLE achieved in the presence of 
MesenCult-XF-derived stromal cells prevented an accurate comparison of colony number 
with other conditions. Scale bar = 200 μm. 
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Figure 7. Expression of cytokeratin 3 in limbal stromal cultures. Confirmation of corneal 
phenotype (via immunostaining for cytokeratin 3) in human limbal epithelial cultures after 
growth in the presence of either murine 3T3 fibroblasts (part B), limbal stromal cells grown 
with 10% foetal bovine serum (part E), or limbal stromal cells grown using the MesenCult-
XF
®
 system (part H). Corresponding staining with Hoechst nuclear dye is displayed in parts 
A, D and G respectively. Inserts in parts B, E & H display negative controls for respective 
cell types. Parts C, F & I show a magnified image of that  in parts B, E & H. Scale bars = 200 
µm. Scale bar in part C corresponds to magnified images in parts C, F & I. 
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Figure 8. Expression of ∆Np63 in limbal stromal cultures. Examination of progenitor cell 
numbers (via immunostaining for ΔNp63) in human limbal epithelial cultures after growth in 
the presence of either murine 3T3 fibroblasts (part B), limbal stromal cells grown with 10% 
foetal bovine serum (part E), or limbal stromal cells grown using the MesenCult-XF
®
 system 
(part H). Corresponding staining with Hoechst nuclear dye is displayed in parts A, D and G 
respectively. Inserts in parts B, E & H display negative controls for respective cell types. 
Parts C, F & I show a magnified image of that  in parts B, E & H. Scale bars = 200 µm. Scale 
bar in part C corresponds to magnified images in parts C, F & I. 
 
 
